A myeloid program associated with COVID-19 severity is decreased by therapeutic blockade of IL-6 signaling.
Hackney JA, Shivram H, Vander Heiden J, Overall C, Orozco L, Gao X, Kim E, West N, Qamra A, Chang D, Chakrabarti A, Choy DF, Combes AJ, Courau T, Fragiadakis GK, Rao AA, Ray A, Tsui J, Hu K, Kuhn NF, Krummel MF, Erle DJ, Kangelaris K, Sarma A, Lyon Z, Calfee CS, Woodruff PG, Ghale R, Mick E, Byrne A, Zha BS, Langelier C, Hendrickson CM, van der Wijst MGP, Hartoularos GC, Grant T, Bueno R, Lee DS, Greenland JR, Sun Y, Perez R, Ogorodnikov A, Ward A, Ye CJ; UCSF COMET Consortium; Ramalingam T, McBride JM, Cai F, Teterina A, Bao M, Tsai L, Rosas IO, Regev A, Kapadia SB, Bauer RN, Rosenberger CM.
Hackney JA, et al. Among authors: bauer rn.
iScience. 2023 Sep 1;26(10):107813. doi: 10.1016/j.isci.2023.107813. eCollection 2023 Oct 20.
iScience. 2023.
PMID: 37810211
Free PMC article.